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The main purpose of this thesis project is to develop and validate a high-
throughput protocol to test drug-drug interactions. As a model, tyrosine kinase inhibitors 
were tested with commonly used antibiotics in Philadelphia chromosome positive 
leukemia patients. Tyrosine kinase inhibitors (TKI’s), such as imatinib mesylate and 
dasatinib, are currently the frontline therapeutic agents for patients with leukemia 
characterized with the presence of the Philadelphia chromosome (Ph+), generated through 
a translocation event between chromosomes 9 and 22 (t[9,22][q34;q11]). However, 
interactions between TKI’s and medications commonly taken by patients with leukemia, 
including antibiotics, have not been significantly studied. In this thesis, a protocol was 
established using innovative, high-throughput technology to determine imatinib and 
dasatinib maximal inhibitory concentrations and possible interactions with drugs that are 
often administered concomitantly with TKI therapy, antibiotics in particular. K562 cells 
were cultured in the presence of TKI’s and cell proliferation was measured. Inhibitory 
concentrations of the TKI’s were determined. Imatinib at concentrations IC10, IC50, and 
IC90 were then co-incubated with co-medications at concentrations reflecting therapeutic 
exposure. Co-medications were gentamicin, ceftazidime, sulfamethoxazole, 
trimethoprim, and a combination of sulfamethoxazole and trimethoprim at a 1:23 ratio, 
respectively, to emulate the constituents of the antibiotic commonly known as Bactrim. 
The results determined that sulfamethoxazole and trimethoprim have no significant effect 
	 	 	
on K562 cell proliferation or the ability of imatinib to reduce K562 cell proliferation. 
Gentamicin and ceftazidime displayed no difference from control perturbation on 
imatinib efficacy. However, gentamicin and ceftazidime were found to have an effect on 
K562 proliferation without the addition of a TKI. Therefore, further investigation is 
necessary to understand the mechanism behind gentamicin and ceftazidime reducing 
K562 cell proliferation. This assay can also be used to assess for potential in vitro TKI-
drug interactions using robust, high-throughput screening techniques.  
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INTRODUCTION 
 
The Philadelphia Chromosome and BCR-ABL 
In 1960, a junior faculty member at the University of Pennsylvania School of 
Medicine, Peter C. Nowell, and a graduate student, David Hungerford, reported a minute 
chromosome in seven patients with chronic myelogenous leukemia (CML).1 This 
unusually small chromosome was designated the “Philadelphia chromosome” after the 
city in which it was discovered.1 The Philadelphia (Ph) chromosome was the first 
evidence that provided support to the hypothesis that a genetic alteration could give rise 
to a tumor from abnormal cell growth.1,2 Later, as cytogenetic technology improved, the 
Philadelphia chromosome was determined to be a translocation between chromosomes 9 
and 22 that resulted in a gene fusion of the Abelson murine leukemia or c-abl oncogene 
from chromosome 9 to the breakpoint cluster region or bcr on chromosome 22 
[t(9;22)(q34;q11)].2–4 This fusion gene encodes the product BCR-ABL1, which is a 
constitutively active tyrosine kinase.4  
The breakpoints in the bcr and abl1 regions are highly variable, but the 
recombination generally involves bcr intron 1, intron 13/14, or exon 19 fusing with abl1 
between exons 1b and 2.4,5 These fusions create three different sized proteins coded as 
p210, p190, and p230.4 p210 is most commonly detected in chronic myelogenous 
leukemia (CML) and occasionally acute lymphoblastic leukemia (ALL) and acute 
myelogenous leukemia (AML).4 Bcr-abl p190 is commonly detected in B-cell ALL but 
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rarely in CML.4 Researchers have discovered that p190 and p210 are formed by different 
mechanisms. Specifically, breakpoints in ALL with p190 bcr-abl suggest that activity of 
the recombinase-activating gene (RAG) is involved whereas there is no indication of 
RAG activity in CML p210 cases.5 p230 is also known as the µ bcr-abl1 transcript, 
generated by a fusion of almost the entire bcr and abl1 genes, and is considered a 
molecular diagnostic marker for neutrophilic-chronic myeloid leukemia (CML-N).4 
Bcr-abl1 is a complex fusion oncogene with multiple domains arising from both 
the BCR and ABL1 regions.4,6 The domains from ABL1 include src homology domains 
(SH1/SH2), which contain an autophosphorylation site that dictates the switch between 
the active and inactive kinase conformation, a proline-rich domain, and DNA- and actin-
binding site domains.4,7 The BCR domains include an N-terminal coiled-coil (CC) 
domain and a Ser/Thr kinase domain (Y177). The N-terminal CC is essential and 
sufficient to activate the ABL1 kinase to induce a myeloproliferative disorder (MPD) in 
mice and the Y177 domain made the induction of MPD more efficient by assisting in 
leukemic cell progenitor expansion, proliferation, and survival.4,8 Another domain within 
BCR is a RAS homolog gene family/Guanine nucleotide exchange factors (Rho/GEF) 
kinase domain.9 Differential activation of the Rho proteins plays a major role in BCR-
ABL1-induced leukemogenesis and the phenotype expressed.9 BCR-ABL1 is located in 
the cytoplasm, which is a prime position to disrupt multiple cystolic and membrane 
signaling pathways.6  
The BCR-ABL1 kinase activity inhibits differentiation, stimulates proliferation, 
and blocks cell death.4 Hyperactivity of this kinase results in activation of signaling 
pathways and interference of normal cellular processes.4 For instance, the JAK/STAT 
	 3	
pathway, which is required for disease initiation, is activated to promote cell 
growth/survival and control BCR-ABL1 stability.10–12 The PI3K-AKT-mammalian target 
of rapamycin (mTOR) pathway is another important downstream cascade in Ph+ 
leukemia because it allows BCR-ABL1 to evade cell cycle arrest.12,13 Activation of the 
RAS/RAF/MEK/ERK pathway and the downregulation of the death receptor ligand, 
TRAIL, prevents apoptosis and results in uncontrolled cell proliferation.4,12 BCR-ABL1 
activity also enhances the expression of the WRN gene to promote genomic instability.4 
The BCR-ABL1 kinase uses these cell pathways to deregulate normal cellular activity; 
however, variation in the expression patterns of BCR-ABL leads to differences in 
leukemia phenotype and phase or progression of the leukemia. 
 
Chronic Myelogenous Leukemia 
 Chronic myelogenous leukemia (CML) is often the myeloproliferative disorder 
characterized by the presence of Philadelphia chromosome. The gene translocation 
t(9;22)(q34;q11) is seen in up to 90% of adult CML cases and is the primary cause for the 
initial phase of CML.6,14 This form of leukemia is distinguished by the increased and 
unregulated growth of mainly myeloid cells or, less commonly, lymphoid cells in the 
bone marrow and blood.4,6 Major symptoms that are associated with CML include 
fatigue, anemia, splenomegaly, episodes of infections, and abdominal discomfort.15 On a 
complete blood count (CBC), CML is suspected when there is an increase of 
granulocytes of all types including basophils and eosinophils.6  
 Worldwide, CML makes up about 15-20% of all leukemias with incidence of 0.7-
1.8/100,000 population, depending on the study considered.6,16 CML is uncommon 
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among children and adolescents: CML constitutes 2% of all leukemias in children 
younger than 15 and 9% of all leukemias in adolescents between 15 and 19 years.17 
Familial occurrence of CML is rare and most patients have no history of increased 
exposure to radiation, but the incidence does rise with exposure to very high levels of 
radiation.6 Survivors of the nuclear bomb explosions in Japan were shown to have an 
incidence of CML that was approximately 50 times higher than subjects that weren’t 
exposed to radiation about 10 years after the explosion.6 Other risk factors include gender 
(CML is slightly more common in males than females), increasing age, and obesity.18,19  
 Untreated CML often progresses through three stages: the chronic phase (CML-
CP), the accelerated phase (CML-AP), and the fatal blast crisis phase (CML-BC).4 
Diagnosis is generally made during the CML-CP and the duration of this phase is 
variable depending on when the diagnosis was made.20 The World Health Organization 
(WHO) defined the criteria for the phases to be the blasts percent of peripheral blood 
white cells or bone marrow cells: CML-CP is less than 10%, CML-AP is 10%-19%, and 
CML-BC is 20% or more.21  
 Most CML patients have the p210 bcr-abl and occasionally a low level of p190 
bcr-abl; patients with the presence of two Ph+ breakpoints generally have a worse 
prognosis than those with a single breakpoint.4,22  
Without therapeutic intervention, CML would progress from CML-CP to CML-
BC through the accelerated phase and the median survival was three years.15 The first 
treatments that were used for patients with CML was interferon-α (IFN-α) therapy and 
stem cell transplantation.15,23 Interferon-α therapy doubled the median survival to six 
years, and patients that underwent stem cell therapy under optimal conditions have a 
	 5	
31.5% chance of living up to ten years.24,25 However, the greatest improvement in therapy 
came when tyrosine kinase inhibitors (TKIs) were discovered, which has radically 
improved patient outcome significantly. Since the development of imatinib treatment, the 
mortality rate is not statistically significantly different than the general population.26 A 
2011 prospective study found that almost 95% of patients that were treated with imatinib 
had a complete cytogenetic response (no Ph+ cells can be measured) six years after 
starting therapy.26 Despite these exceptional advances in CML therapy, 20-25% of 
patients experience imatinib resistance, mostly due to mutations in the BCR-ABL1 
protein.27 Second-generation TKIs and targeting different cellular pathways have helped 
circumvent resistance and research of future treatment options is continuous in order to 
improve the survival of patients with CML.  
 
Acute Lymphoblastic Leukemia 
 There are an estimated 6,000 new cases of Acute Lymphoblastic Leukemia (ALL) 
in the United States annually.28 While ALL occurs in both children and adults, 
approximately 60% of patients are <20 years of age and ALL is known as the most 
common childhood cancer.28,29 The Philadelphia chromosome can also be found in some 
patients with acute lymphoblastic leukemia (ALL). Approximately 20-30% of adult ALL 
patients and 3-4% of pediatric ALL patients have this translocation that leads to the 
creation of the BCR-ABL1 kinase.30,31 ALL is characterized by the accumulation of 
lymphoblasts (immature white blood cells) in the bone marrow.32 Major symptoms that 
are associated with ALL are similar to patients with CML and they include enlarged 
lymph nodes, splenomegaly, fatigue, bone or joint pain, and enlarged thymus.33 The 
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clinical presentation of Ph+ ALL is indistinguishable from ALL with other abnormalities 
and diagnosis requires cytogenetic or fluorescence in situ hybridization (FISH) detection 
of the bcr-abl1 translocation.30 
 Similar to CML, ionizing radiation is an established causal exposure for 
childhood ALL, but etiology is often not established.28 An abnormal response to common 
infections and Down’s Syndrome are other factors that have shown to correlate with 
ALL; however, it is difficult to determine relevant exposures or genetic variants because 
of the many biologically distinct subtypes of ALL.28 
ALL is classified into different subtypes based on hematopoietic origin of 
leukemic cells and degree of cell maturation.34 B-cell ALL is a neoplasm of B-cell 
precursors (B-lymphocytes) and T-cell ALL is characterized by expansion of immature 
T-lymphocytes. Twenty to 30% of adult B-cell ALL cases involve the Philadelphia 
chromosome, but Ph+ T-cell ALL is rare and only a few cases have been reported in the 
literature.35 
Ph+ ALL patients mostly express the p190 bcr-abl1 transcripts, which only retains 
the first exon of BCR.4,30 A larger protein, with the p210 breakpoint, is seen in 30% of 
adult and 20% of childhood patients with Ph+ ALL.4 The p190 breakpoint has shown to 
have stronger transforming activity compared to p210, which could be due to a broader 
substrate range in the p190 protein.30 
Prior to the use of tyrosine kinase inhibitors, chemotherapy without hematopoietic 
stem cell transplantation (HSCT) showed prognosis for both pediatric and adult patients 
with Ph+ ALL as very poor, with less than 5% of adults being cured.4,30 The introduction 
of imatinib showed improvement in response rates and survival; 73% of adult patients 
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had a significant reduction in marrow or peripheral blasts when treated with imatinib and 
the 3-year event free survival (EFS) rate for pediatric patients went from 35% to 80% 
when treated with a combination therapy of imatinib and chemotherapy.30,36 However, 
survival rates for children and adults with Ph+ ALL are still much lower compared to 
other types of ALL.30,37 More research needs to be done to determine the effectiveness of 
combined HSCT, chemotherapy, and/or TKI therapies for both children and adults.36 
 
Acute Myeloid Leukemia 
 Acute myeloid leukemia (AML) is also seen with the Philadelphia chromosome 
translocation. AML is the most common acute leukemia in adults, accounting for 
approximately 80% of leukemia cases, and constitutes 20% of pediatric leukemia 
cases.38,39 However, the bcr-abl1 transcripts are seen in less than 1.5% of patients with 
AML.4 
 AML is a type of cancer that is characterized with abnormal myeloblasts, red 
blood cells, or platelets development.40 When the Philadelphia chromosome is detected in 
patients with AML, it is often cytogenetically indistinguishable between CML-BC.4,41 
Despite the similarities, Ph+ AML appears with distinct features from CML-BC including 
fewer cases with splenomegaly, less peripheral basophils, lower bone marrow cellularity, 
and a lower myeloid/erythroid ratio.4,41,42 Additionally, the breakpoint on chromosome 22 
differs between CML in approximately 50% of the cases.4 The p210 and p190 
breakpoints can both be observed in AML patients, whereas the p190 breakpoint is rarely 
observed in CML.4 Research indicates that there is a higher rate of relapse with AML 
patients that have the p190 breakpoint.43 
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 The median survival time of Ph+ AML is 9 months, which is very similar to the 7-
month median survival of myeloid CML-BC patients.4 Effective therapeutic strategies are 
lacking. However, survival improved with the implementation of tyrosine kinase inhibitor 
therapy, especially when combined with chemotherapy and HSCT, by increasing the 
median survival rate from 9 months to 18 months.43 
 
BCR-ABL1 Tyrosine Kinase Inhibitors 
 Chronic myeloid leukemia is a unique disease because it appears to be the result 
of a single biochemical defect and, therefore, the BCR-ABL protein is a logical target for 
therapeutic intervention. Signal transduction inhibitor-571 (STI-571), also known as 
imatinib mesylate, Gleevec (United States), or Glivec (Europe), was discovered after 
researchers searched for a drug that inhibited the BCR-ABL kinase.44 However, 500 
protein kinases were found during studies of the human genome and many researchers 
and clinicians feared the toxic effects that may occur with the use of a kinase inhibitor.45 
Nevertheless, imatinib received Food & Drug Administration (FDA) approval in May 
2001 for the treatment of multiple cancers, including Ph+ CML.46 With the success of 
imatinib, other tyrosine kinase inhibitors have been developed to inhibit different types of 
mutations and forms of resistance found in patients with Ph+ leukemia. 
 
First-Generation Tyrosine Kinase Inhibitor 
 Imatinib is considered a first-generation tyrosine kinase inhibitor because it was 
the first drug approved to specifically target the BCR-ABL1 tyrosine kinase protein. The 
BCR-ABL1 tyrosine kinase catalytic domain has two lobes, the N-terminal lobe (N-lobe) 
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and the C-terminal lobe (C-lobe).47 In the inactive state, the activation loop, which has a 
key role in the activation of the kinase, is folded in toward the ATP binding site.47 
Imatinib binds the kinase in the inactive state between the N- and C-lobe and spans most 
of the kinase’s width.47 Imatinib binds close to the adenosine triphosphate (ATP) binding 
site, which locks it in a closed conformation.4 Inhibiting the phosphorylation of ATP 
prevents the switch to the active or “open” conformation, which blocks downstream 
signaling pathways.4,48 Imatinib has a high affinity for the Abl kinase and is inactive 
against Ser/Thr-kinases and most normal functioning tyrosine kinases.48 Imatinib also 
inhibits the c-KIT and PDGFR tyrosine kinases that play a role in gastrointestinal stromal 
tumor (GIST) formation.49 
 Initial studies with imatinib in rats and dogs demonstrated that bioactive 
concentrations of imatinib are readily achieved in the circulation.50 Administration of 
imatinib 3 times per day, which assured a continuous block of BCR-ABL1 activity, over 
11 days cured 87-100% of the treated mice, whereas once or twice per day did not.51 This 
study demonstrated that continuous exposure to imatinib is necessary for success. 
Pharmacokinetic studies demonstrated that the half-life for imatinib is 12-14 hours and 
that predicted effective concentrations correlated well with preclinical trials.50 Currently, 
clinical guidelines recommend frontline treatment of Ph+ CML-CP to be oral 
administration of 400 mg/day and 600 mg/day if the disease has progressed to CML-AP 
or CML-BC.52 These dosages are similar for other Ph+ leukemias including Ph+ ALL.52 
Some side effects of imatinib treatment include rash, weight gain, edema, pleural 
effusion, cardiac toxicity, nausea and vomiting, arthralgias and myalgias, and 
myelosuppression.53   
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 The development of imatinib has increased the survival of CML immensely 
compared to the previous standard of care, IFN-α. In a randomized study comparing 
ST1571 (imatinib) and Interferon, they showed that imatinib had higher rates of major 
molecular response, complete cytogenetic response, and long-term and transformation-
free survival.54 In CML-CP, the median 8-year survival rate was ≤15% before 1983, 
42%-65% from 1983-2000, and 87% since 2001 – the year that imatinib mesylate was 
FDA approved.25 In CML-AP, the 8-year survival is 75% since 2001.25 The survival of 
patients in CML-BC has only modestly improved since the introduction of imatinib: the 
median survival went from 6 months to 7 months since 2001.25  
Despite the success of imatinib treatment, 33% of patients have shown to have an 
unfavorable outcome primarily because they become resistant to this therapy.55 Patients 
required monitoring while being treated with imatinib to identify failure and suboptimal 
responses. Patients classified with failure and suboptimal response undergo dose 
escalation.55,56 Patients who had a failed response and then increased their daily dose of 
imatinib from 400 mg to 600-800 mg showed to have a significant improvement.55 In a 
recent study investigating imatinib dose escalation, 42% of patients who had their dose 
escalated obtained a cytogenetic response within 12 months.57 While dose escalation is a 
viable treatment option for patients after failure of the standard dose of imatinib, it is not 
effective for all patients and the use of second-generation TKIs is also recommended.  
 
Second-Generation Tyrosine Kinase Inhibitors 
 Mechanisms of resistance to imatinib have been extensively investigated, which 
lead to the development of second-generation TKIs. The first drug approved by the FDA 
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as a second-line treatment for Ph+ CML-CP, -AP, and –BC was dasatinib in 2006.55 
Dasatinib (Sprycel) has a different chemical structure compared to imatinib, which binds 
the inactive and active forms of BCR-ABL1 and has greater activity against BCR-ABL1 
compared to imatinib.58,59 Dasatinib also has inhibitory activity against many of the 
imatinib-resistant BCR-ABL1 mutations.60  
 The START-C trial, a multicenter, phase 2 trial, assessed patients with CML-CP 
who demonstrated imatinib resistance or intolerance and initiated a twice-daily dasatinib 
regimen.60 This trial found that 62% of patients obtained major cytogenetic response and 
53% had a complete cytogenetic response, which confirmed the use of dasatinib 
treatment to treat relapse or resistant CML.60 The START-R trial compared dasatinib 
treatment to high-dose imatinib treatment and observed a higher percentage of patients 
treated with dasatinib achieving a complete cytogenetic response compared to imatinib, 
44% and 18%, respectively.55,61 Additionally, dasatinib has been reported to be effective 
against CML-AP and –BC. The START-A trial demonstrated complete cytogenetic 
responses were achieved in 32% of patients with CML-AP.62 Complete cytogenetic 
responses in CML-BC patients differed depending on the whether patients had myeloid 
blast phase (26%) or lymphoid blast phase (46%) CML.63 
 The recommended starting dose for patients with Ph+ CML-CP is 100 mg once 
daily and 140 mg once daily for patients with CML-AP or –BC.58 Some common side 
effects that impact approximately 30% of patients include low blood counts, fluid 
retention (pleural effusion or pericardial effusion occur in about 9% of cases), diarrhea, 
headache, bleeding, muscle and bone pain, fatigue, fever, rash, nausea, and infection.64 
 Another second-generation TKI, nilotinib (Tasigna), was approved to use as 
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second-line treatment for CML in 2007.58 Nilotinib results from modifications to the 
imatinib molecule to create more favorable interactions and a better fit into the 
hydrophobic ATP binding space of the inactive conformation of BCR-ABL1.65 These 
changes resulted in a drug 30 times more potent than imatinib with increased selectivity 
for the ABL protein and less cross reactivity with other molecules including PDGFR and 
KIT.55,65  
 The recommended dosing schedule for nilotinib is 400 mg twice daily, which was 
approved based on a Phase 2 study with CML-CP and –AP patients who failed initial 
imatinib therapy.58 This study showed that 46% of these patients had a complete 
cytogenetic response when given nilotinib.58 However, the efficacy of nilotinib appears to 
be lower in advanced disease. Only 19% of patients with CML-AP showed a complete 
cytogenetic response and only 25% of CML-BC patients achieved a complete 
hematologic response.58 
 The most common adverse events seen with nilotinib include bone marrow 
suppression (neutropenia, thrombocytopenia, and anemia) and asymptomatic serum 
lipase elevations.58 Cardiac adverse events are also more common with nilotinib than 
imatinib or dasatinib: QTc-interval prolongation and palpitations have been reported in 1-
10% of patients.58 Other side effects include rash, pruritus, headache, nausea, fatigue, and 
liver toxicity.65  
 After the failure of imatinib, it is necessary to decide which second-generation 
TKI would be most effective for each patient. Analysis of imatinib resistant CML-CP 
patients was performed to understand the impact of various BCR-ABL mutations and the 
impact of those mutations on dasatinib or nilotinib therapy.66 Dasatinib was effective 
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regardless of most mutations; only a subgroup of patients had mutations that caused a less 
favorable outcome (Q252H, E255K/V, V299L, and F317L).66 Treatment with nilotinib 
showed similar results, but the mutations that were less sensitive to nilotinib therapy 
included E255K/V, Y253F/H, and F359C/V.66 These studies indicated that most patients 
have similar responses with dasatinib and nilotinib except for a few particular mutations 
where treatment should be chosen carefully. Another consideration to take when 
choosing second-generation TKI treatment is the potential adverse events that may be 
more pronounced based on the patient’s comorbidities. For example, pleural effusion is 
more common in patients receiving dasatinib treatment, so patients with risk factors for 
pleural effusion such as hypertension and chronic obstructive pulmonary disease are at 
greater risk for developing complications.66 
 Subsequent clinical trials of nilotinib and dasatinib have been performed to 
determine whether second-generation TKIs should be expanded to be included in first-
line therapy.67,68 Although there is limited information on the long-term response rate of 
these TKIs as first-line therapy, one study evaluated the efficacy and safety of using these 
drugs for first-line treatment.68 It was determined that second-generation TKIs can be 
safely used as therapy for patients with CML-CP.68  
 
Third-Generation Tyrosine Kinase Inhibitor 
 After the failure of imatinib and second-generation TKIs, or in the presence of the 
T315I mutation that all first- and second-generation TKIs are ineffective against, a third-
generation tyrosine kinase inhibitor may be considered. Ponatinib (Iclusig) is an oral 
third-generation TKI able to inhibit native BCR-ABL1 proteins and most of the clinically 
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relevant BCR-ABL1 mutations, including the T315I mutation.69 This drug was developed 
using a structure-based approach to design a small TKI that can access the ATP binding 
site of mutated BCR-ABL that block the access of imatinib, dasatinib, and nilotinib.70  
Ponatinib is currently approved for patients with CML who are resistant or 
intolerant to previous TKI therapy. A phase 2 trial was conducted and they found that 
46% of 267 patients with CML-CP had a complete cytogenetic response (40% of patients 
with resistance to or unacceptable side effects from dasatinib or nilotinib and 66% of 
patients with the T315I mutation).71 There were no BCR-ABL mutations that conferred 
resistance to ponatinib detected.71 However, 12% of the patients in this study 
discontinued use due to adverse events caused by ponatinib including serious arterial 
thrombotic events.71 Congestive heart failure, fluid retention, pancreatitis, and 
hemorrhagic events were also recorded in the patients in the trial.60 Due to these severe 
risks associated with ponatinib, this drug is only indicated for patients who are T315I-
positive or patients for whom no other TKI is indicated.67 
 
Tyrosine Kinase Inhibitor Resistance 
 Imatinib is considered the standard of care in CML management and has shown to 
have superior results compared to past therapies. However, approximately one-third of 
CML patients treated with imatinib do not achieve complete cytogenetic response due to 
factors including drug resistance.72 Also, more than 80% of Ph+ ALL patients have 
reported resistant mutations at time of relapse.30 Patients that fail to achieve hematologic, 
cytogenetic, or molecular responses are considered primarily resistant, and those losing 
previously obtained milestones are deemed secondarily resistant.27 The mechanisms of 
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resistance to imatinib can be either BCR-ABL dependent (point mutations or gene 
amplification) or BCR-ABL independent.72  
 Treatment failure is often due to point mutations in the BCR-ABL kinase domain. 
Over 100 different point mutations have been characterized; the most frequent mutations 
occur in the ATP phosphate-binding activation loop.72 F317 and T315I were the most 
common mutations with dasatinib, and Y253H and T315I were predominant with 
nilotinib.73 Thus, cross-resistance is limited to T315I, which is known as the gatekeeper 
mutation, and results when a single threonine to isoleucine nucleotide substitution occurs 
in the activation loop.72 The other BCR-ABL-dependent mechanism of resistance is 
amplification; however, this is a less common mode of treatment failure.27,72  
 BCR-ABL-independent mechanisms of resistance include the increased or 
decreased expression of drug influx and efflux transporters and other molecules that 
inhibit the activity of imatinib or other tyrosine kinase inhibitors. Increased expression of 
the P-glycoprotein (P-gp) drug efflux pump MDR1 was found in patients with CML, and 
silencing of MDR1 by RNAi restored imatinib susceptibility to previously resistant 
lines.74 Another study demonstrated that patients with lower levels of the drug uptake 
human organic cation transporter 1 (hOCT1) led to decreased drug uptake, and when 
hOCT1 levels were increased, patients had a much higher chance of achieving a major 
molecular response (MMR).75 Other factors that cause imatinib resistance include 
sequestration of imatinib in the plasma by serum protein α1-acid glycoprotein, lower 
serum imatinib concentration, and alternative signal pathway activation through 




 Infection is one of the most common, and serious, complications that can occur in 
cancer patients and various antibiotics are used to treat this depending on the type of 
infection. The most common antibiotics used include sulfamethoxazole/trimethoprim, 
gentamicin, and ceftazidime.  
 
Bactrim (Sulfamethoxazole/Trimethoprim) 
 Bactrim is a combination of two drugs sulfamethoxazole/trimethoprim known by 
a variety of names including SMX/TMP, co-trimoxazole, Bactrim, Septra, and 
Sulfatrim.78 This medication is active against gram-positive and gram-negative 
microorganisms.78 It is administered orally or by an intravenous (IV) fusion.78 SMX/TMP 
or Bactrim is approved for use in patients from 2 months of age to adulthood.78 In both 
the pediatric and adult cancer population, SMX/TMP is commonly used prophylactically 
and empirically.79  
 Contraindications of SMX/TMP use include known hypersensitivity to 
sulfonamides or trimethoprim, documented megaloblastic anemia due to folate 
deficiency, pregnant/nursing women, and children <2 months of age.78,80 Some adverse 
effects have occurred in patients using this medication including body aches, blistering 
skin, rash, fever, sun-sensitivity, and diarrhea.81 Other severe warning that are listed on 
the FDA drug safety label requirements include thrombocytopenia, Stevens-Johnson 
Syndrome, toxic necrolysis, MRSA development, folate deficiency, hemolysis, and 
hypoglycemia.80 Interactions with SMX/TMP have been found with other drugs 
including antidepressents, antibacterials, antivirals, anticoagulants, diuretics, 
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cyclosporine, and methotrexate.78 
 The Bactrim tablet is composed of trimethoprim and sulfamethoxazole at a ratio 
of 1:5 and administered orally or through IV fusion. 78 These medications are then widely 
distributed into body tissues and fluids.78 These two drugs are more effective when given 
together than when given separately because they inhibit successive steps in the folate 
synthesis pathway.82 Sulfamethoxazole blocks the synthesis of dihydropteroic acid from 
para-aminobenzoic acid and pteridine; trimethoprim then acts to inhibit the reduction of 
dihydrofolic acid to tetrahydrofolic acid by the inhibition of the enzyme dihydrofolate 
reductase.82 The inhibition of the biosynthesis of tetrahydrofolic acid interrupts the 
bacterial synthesis of purines, thymidine, serine, and methionine, which are all essential 
to the function of microbes.82 Both sulfamethoxazole and trimethoprim are excreted in 




 Gentamicin sulfate is an antibacterial medication sold under the brand name 
Garamycin and is used to treat serious gram-negative bacterial infections.83 It is 
administered by IV infusion or intramuscular (IM) injection.83 
 Gentamicin is a commonly used antibiotic routinely given to hospitalized 
newborns, children, adults, and the elderly.84,85 Pediatric oncology patients are often 
given gentamicin as treatment for fever and neutropenia, but the pharmacokinetic profile 
changes depending on age and chemotherapy treatment, which requires varied dosing 
parameters.86 Gentamicin use in adult patients with AML also requires dosage 
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variation.87 
 Gentamicin has been known to cause ototoxicity, which can lead to temporary or 
permanent hearing loss and/or loss of balance, and nephrotoxicity, which leads to a 
buildup of urine and wastes.83 Gentamicin has also been reported to cause neuromuscular 
blockade, respiratory paralysis, allergic responses, low blood counts, and fetal 
nephrotoxicity.83 Interactions with gentamicin have been found with other drugs 
including β-lactam antibiotics, carbapenems, chloramphenicol, clindamycin, diuretics, 
neuromuscular blocking agents, NSAIDs, and tetracyclines.83 
 Gentamicin cannot be absorbed by the gastrointestinal tract and must be given 
parenterally.83 The mechanism of action of gentamicin is similar to other 
aminoglycosides, which work by binding to the bacterial 30S ribosomal subunit, leading 
to a misreading of the t-RNA, and this leaves bacteria unable to synthesize proteins 
essential to growth.88 The gentamicin complex is composed of three main parts, which 
make up approximately 80% of gentamicin: gentamicin C1, gentamicin C1a, and 
gentamicin C2.89 These major components mainly differ in the degree of methylation in 
the 2-amino-hexose ring and the ratio between these components is highly variable 
depending on the manufacturing process.90 The remaining 20% is composed of 
gentamicin groups A and B, gentamicin X, and some others.89 The half-life of gentamicin 
is 2-3 hours and is eliminated by glomerular filtration within 24 hours of administration.83 
 
Ceftazidime 
 Ceftazidime is a β-lactam antibiotic and third-generation cephalosporin.91 It is 
also known as Fortaz or Tazicef.91 Ceftazidime is used for the treatment gram-negative 
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and gram-positive aerobes and anaerobes.91 It is administered by injection into a vein or 
muscle.91 Ceftazidime is commonly used in patients with leukemia to treat bacterial 
infections, but a higher dose may be necessary to maximize drug exposure.92 
 Some common side effects that may occur while taking ceftazidime include 
allergic reactions, nausea, and pain at the site of injection. More severe side effects 
include emergence of Clostridium difficile, C. difficile-associated diarrhea and colitis, and 
neurotoxicity.91 Drug interactions can occur with aminoglycosides, chloramphenicol, 
probenecid, and glucose tests.91 
 Peak serum concentrations of ceftazidime are attained approximately 1 hour after 
administration of the dose and becomes widely distributed into body tissues and fluids.91 
Ceftazidime has a high affinity for the enzymes responsible for cell-wall synthesis, 
especially penicillin-binding proteins (PBP’s).93,94 Ceftazidime causes filamentation and 
eventual cell lysis of bacteria due to its activity against PBP-3; this suppression also 
inhibits the bacteria’s cell division capabilities.94 Ceftazidime’s half life is 1.4-2 hours 
and is completely eliminated in the urine by glomerular filtration approximately 24 hours 
after administration.91 
 
Drug Interactions in Cancer Therapy 
 Polypharmacy is commonly defined as the concomitant use of five or more 
drugs.95 Polypharmacy is associated with an increased risk of drug-drug interactions 
leading to a decrease or potentiation of a drug’s efficacy and/or adverse health 
outcomes.95  
 Drug-drug interactions can be classified as pharmacokinetic or pharmacodynamic. 
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Pharmacokinetics investigates the movement of the drug in the body including the 
processes of absorption, distribution, metabolism, and excretion.96 Pharmacodynamics 
refers to an observed effect at the site of action resulting from a certain drug 
concentration and can occur when two drugs with similar mechanisms of action are 
combined.96 Pharmacokinetic interactions can occur at any site in the body that involves 
absorption, distribution, metabolism, or excretion, whereas pharmacodynamic 
interactions happen on pharmacological receptors, signal transduction mechanisms, or 
physiological systems.97 Consequences of pharmacokinetic or pharmacodynamic 
interactions are described as synergy, potentiation, or antagonism. Polypharmacy is 
common among the elderly and patient populations who are likely to be prescribed many 
medications, including cancer patients.    
Cancer patients are particularly susceptible to drug-drug interactions because they 
often receive multiple medications – along with drugs to treat comorbid conditions, 
patients receive medications to treat cancer-related symptoms or therapy-induced toxicity 
including pain and infection.98 In a study examining 405 cancer patients, one-third of the 
patients were exposed to at least one drug-drug interaction and 86% of these interactions 
were classified as major or moderate.98 Additionally, the risk factor for potential drug 
interactions increased with an increased number of medications.98  
 Imatinib has been shown to have interactions with specific drugs, even though the 
interactions with many drugs that CML patients frequently take are still unknown. 
Imatinib is mainly metabolized by the cytochrome p450 isoenzyme 3A4 and is a 
substrate of the human organic cation transporter type 1 (hOCT1), P-glycoprotein (Pgp), 
and the breast cancer resistance protein (BCRP).99 Therefore, when inhibitors of the 
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CYP3A family are given, such as levothyroxine, voriconazole, or amiadorone, there are 
pharmacokinetic interactions that can alter the plasma levels of imatinib.99–102 The 
pharmacokinetic profile of imatinib was also significantly altered by CYP3A4 inducers 
like St. John’s wort and rifampicin, antacids that elevate gastric pH, and inhibitors of 
hOCT1.99,103–105 These pharmacokinetic interactions are clinically relevant because 
clinicians have to alter treatment and dosage depending on coadministered drugs that may 
be effecting the absorption, distribution, or elimination of the therapy drug. Also, 
pharmacokinetic interactions may increase imatinib exposure to cells, and 
pharmacodynamic interactions may be a consequence of this increased exposure.  
 Antibiotic medications are often administered to patients with cancer while 
receiving anticancer treatments including imatinib. These patients are vulnerable to 
pharmacokinetic or pharmacodynamic interactions. For example, both imatinib and 
sulfamethoxazole are known competitive inhibitors of CYP2C9, a hepatic enzyme known 
for metabolizing many drugs, and this may affect the concentration or the effect of 
SMX/TMP or imatinib in patients.106,107 Other anti-infective agents have been known to 
alter imatinib exposure in patients including clarithromycin, erythromycin, ciprofloxacin, 
levoflaxicin, and many others mostly due to interactions with CYP3A4, CYP2C9, 
hOCT1, or Pgp.99  
Renal impairment can be another factor that contributes to the change in the 
pharmacokinetics of imatinib. Antibiotics are often responsible for causing acute renal 
injury (AKI), with 18% of hospitalized patients developing AKI during their stay while 
being treated for an infectious disease.108 When assessing patients with cancer that had 
varying degree of renal impairment, the mean imatinib exposure increased 1.5- to 2-fold 
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compared to patients with normal renal function.109 This can lead to adverse drug 
reactions with imatinib and it is important for clinicians to continually monitor this anti-
cancer therapy when these reactions occur. 
Despite the many pharmacokinetic interactions with imatinib described, the 
clinical relevance of many pharmacodynamic interactions with imatinib is unknown in 
adult Ph+ leukemia patients.110 Identifying the effects of possible interactions between 
antibiotic medications commonly taken by patients with Ph+ leukemia will help clinicians 
optimize TKI therapy and help improve patient care.  
 
Assay Development 
 Analytical assays are important methods required to understand and measure 
properties of a target, such as cells, drugs, or other biochemical substances. They can be 
used to identify drug interactions that may results in synergy or antagonism. Cell-based 
assays can measure the function of the target in the context of the cell, including cell 
viability and proliferation. Constructing an assay that is specific, sensitive, and robust is 
crucial in many areas of research, drug development, and clinical use.111 Assay 
development requires identifying the purpose of the analytical method, determining the 
method and the necessary steps required, establishing specification limits, performing a 
risk assessment, and validating the measurement performance.112 Some key 
considerations in assay development include robustness, reliability, practicality, cost, and 
automation.113  
 Cell-based assays that test for cell viability are often used to screen different 
compounds and their effect on cell proliferation. There are a number of different assay 
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methods use to test for cell viability including tetrazolium reduction, resazurin reduction, 
protease markers, and ATP detection.114 Each cell viability assay has associated 
advantages and disadvantages. ATP detection is the easiest and fastest to perform, the 
most sensitive, and has the least amount of interference, while the resazurin and 
tetrazolium compounds are less expensive alternatives.114 Cell-based assays aim to mimic 
the in vivo cellular environment, and these types of assays are becoming a common 
method to test variations in cellular conditions. 
 
Purpose and Goals of Thesis Project 
 The main purpose of this thesis project is to develop high-throughput screening 
technology to test potential anticancer therapy drugs and frequently concomitantly 
administered drugs and to determine whether the antibiotics bactrim, gentamicin, and 
ceftazidime, which are commonly used for prevention and treatment of bacterial 
infections in leukemia patients, can interfere with the antileukemia therapy imatinib in 
patients with Ph+ leukemia. This will help clinicians optimize TKI therapy and improve 
patient care. The goals of this project is to develop a protocol for in vitro testing that can 
be used in the future to determine other TKI-drug interactions: 
• Establish optimal cell proliferation conditions for a high-throughput assay. 
• Establish inhibitory concentrations of TKI’s, imatinib and dasatinib on Ph+ cell 
line K562 proliferation. 
• Determine the effects of the commonly used antibiotic medications bactrim, 
gentamicin, and ceftazidime on cell growth of the Ph+ cell line K562 treated with 
imatinib. 
MATERIALS AND METHODS 
 
Reagents 
 Imatinib mesylate, dasatinib, gentamicin sulfate (≥590 µg gentamicin base per 
mg), sulfamethoxazole, trimethoprim, and ceftazidime were purchased from Sigma-
Aldrich (St. Louis, MO) and stored at 4°C protected from light. Prior to experiments, 
imatinib mesylate and dasatinib were dissolved in DMSO (Thermo Fisher Scientific, 
Waltham, MA) while gentamicin sulfate, sulfamethoxazole, trimethoprim, and 
ceftazidime were dissolved in distilled H2O with 0.3% Tween 20 (solutions based on 
recommendations by Tecan technical support for optimized instrument dispensing). 
RPMI-1640 cell culture media, fetal bovine serum, penicillin-streptomycin-amphotericin, 
and L-glutamine were purchased from Thermo Fisher Scientific.  
 
Cell Culture 
K562 is a nonadherent cell line derived from a patient with Philadelphia 
chromosome positive chronic myelogenous leukemia.115 K562 cells were obtained from 
American Type Culture Collection (Manassas, VA) and maintained according to the 
recommended protocol. Briefly, cells were incubated in complete media comprised of 
RPMI-1640 media supplemented with 10% fetal bovine serum, penicillin-streptomycin-
amphotericin [10µg/mL], and L-glutamine [2mM] at 37°C and 5.5% CO2. Cells were 
passed when reached 80% confluency. The complete media was stored at 4°C and 
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warmed to 37°C when added to the culture. K562 cells were collected at the first, second, 
and third passage for freezing. Frozen stocks of K562 cells were stored in liquid nitrogen 
suspended in a 10% DMSO and complete media solution.  
 
 Cell Seeding Density Determination 
 A stock concentration of K562 cells (8 x 104 cells/mL or 2,000 cells/25 µL) was 
used to make twofold serial dilutions of 25 µL/well in complete RPMI media into a 384-
well plate. These dilutions were done in triplicates. Final cell concentrations ranged from 
2,000 K562 cells/25 µL to 31 K562 cells/25 µL. Each sample was plated in triplicate. 
Cell proliferation was measured at time 0 hours, 24 hours, 48 hours, and 72 hours. 
Number of cells present in each well was counted in a hemocytometer under a 
microscope using trypan blue exclusion of dead cells. The trypan blue dye exclusion 
protocol used was developed from Current Protocols in Immunology, 2015.116 Living 
cells have intact cell membranes, which exclude certain dyes, such as trypan blue, from 
entering into the cell, whereas dead cells do not. Therefore, cells positive for trypan blue 
dye have compromised membrane integrity, indicating loss of viability. The procedure 
outline an equal amount of cell suspension mixed with 0.4% trypan blue. A drop (10 µL) 
was applied to a hemacytometer, and the unstained (viable) cells were counted under a 
light microscope. The percentage of viable cells was then calculated. This experiment 
was repeated twice in triplicate. This assay was performed to measure K562 cell 
proliferation within a 72-hour period and to determine a reliable time of drug 
administration (when the cells are in exponential phase and growing freely).  
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CellTiter-Glo® Luminescent Cell Viability Assay 
 After optimal cell concentrations were determined, the CellTiter-Glo® 
Luminescent Cell Viability Assay was used to determine the number of viable cells 
present in each well.  The CellTiter-Glo® Luminescent Cell Viability Assay (Promega, 
Madison, WI) was performed according to the manufacturer recommendations. 117 The 
assay is based on the measurement of the ATP present, which is proportional to the 
number of metabolically active cells present in culture. Mono-oxygenation of luciferin 
(present in the CellTiter-Glo® Reagent) is catalyzed by luciferase (also present in the the 
CellTiter-Glo® Reagent) in the presence of Mg2+, ATP, and molecular oxygen. Briefly, 
the CellTiter-Glo® Buffer (100 mL) was added to the lyophilized CellTiter-Glo® 
Substrate at room temperature (23°C) to create the CellTiter-Glo® Reagent. This Reagent 
was added in equal volume to the medium containing cells present in each well (25 µL). 
The plate was incubated at room temperature for 20 minutes protected from light. 
Luminescence was recorded using the Synergy™ Neo2 Multi-Mode Microplate Reader 
(BioTek, Winooski, VT). 
K562 cells at concentration 3.36 x 106 cells/mL or 84,000 cells/25 µL in complete 
media were plated into a 384-well plate and serial twofold dilutions were made with four 
replicates via pipette. The dilutions ranged from 84,000 K562 cells/25 µL to 328 K562 
cells/25 µL. A larger range of cell concentrations were used compared to the previous 
experiment because this wider range of cells accounted for the proliferation of cells after 
the culture period. Plates with cells were wrapped in water moistened paper towels (based 
on recommendation from the Drug Discovery Core Director to prevent evaporation) and 
kept at 37°C in 5.5% CO2. After 1 hour, resting cell viability was measured using the 
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CellTiter-Glo® Luminescent Cell Viability Assay.  
 
Imatinib and Dasatinib Inhibitory Concentration Determination 
 K562 cells in complete media were dispensed into a 384-well plate from a stock 
concentration of 8 x 104 cells/mL or 2,000 cells/25 µL based on experimental data using 
the Freedom EVO® liquid handling workstation (Tecan, Männedorf, Switzerland, Figure 
1A). Immediately following cell dispensing, lids were placed on the 384-well plate, 
wrapped with a water moistened paper towel, and stored at 37°C in 5.5% CO2. After 
incubation for 24 hours, cells were exposed to a tyrosine kinase inhibitor (imatinib 
mesylate or dasatinib). TKI’s were dispensed using the HP D300 Digital Dispenser 
(Hewlett-Packard, Palo Alto, CA, Figure 1C). Imatinib mesylate was diluted to a top 
stock concentration of 10 mM and dasatinib was diluted to a top stock concentration of 5 
mM. Imatinib concentrations that were tested ranged from 30 µM to 3.17 nM with ½ log 
and 1:1.3 distributions. Dasatinib concentrations that were tested ranged from 10 µM to 
0.5 pM with ½ log and ¼ log distributions. Percent DMSO was kept constant across the 
wells. Drug dispensing protocols were established to reduce the occurrence of edge 
effect. Figure 1B shows the protocol for imatinib distribution into the 384-well plate 
using the program for the HPD300 Digital Dispenser. After the drugs were dispensed, 
plates were covered with a water moistened paper towel and kept at 37°C in 5.5% CO2 
for 48 hours prior to performing cell proliferation assays. Seventy-two hours after the 
start of the experiment, cell proliferation was determined using the CellTiter-Glo® 
Luminescent Cell Viability Assay and a Synergy™ Neo2 Multi-Mode Microplate Reader 





Figure 1. Diagram depicting the protocol used to determine TKI inhibitory 
concentrations and antibiotic perturbation on TKI efficacy. The following pictures 
were taken at the drug Discovery Facility at the University of Utah: A) Freedom 
EVO® liquid handling workstation. B) HPD300 Digital Dispenser Software with 
example dispensing protocol. C) HPD300 Digital Dispenser. D) Synergy Neo2 Multi-
Mode Microplate Reader.  
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Jolla, CA) to determine inhibitory concentrations (IC10, IC50 (half maximal), and IC90) of 
imatinib and dasatinib based on residual viable cells across three independent 
experiments. 
 
Assessing Potential Antibiotic Perturbation of TKI Efficacy 
 Once the IC10, IC50, and IC90 for imatinib were determined, these concentrations 
were tested with different antibiotics (gentamicin, sulfamethoxazole, trimethoprim, and 
ceftazidime) at concentrations reflecting clinically relevant exposures.118–120 
K562 cells were dispensed into five 384-well plates using the same protocol as for 
the inhibitory concentration experiment (see above). After 24 hours, TKI plus antibiotic 
agent were dispensed into the plates using the HP D300 Digital Dispenser to reflect a 
pure co-administration. Imatinib mesylate was diluted to the concentration 5 mM using 
DMSO. Gentamicin sulfate, ceftazidime, sulfamethoxazole, and trimethoprim were 
diluted to 10 mM with distilled H2O plus 0.3% Tween 20. Gentamicin concentrations that 
were tested ranged from 200 µM to 0.5 µM. Ceftazidime concentrations ranged from 300 
µM to 10 µM, sulfamethoxazole ranged from 1 mM to 10 µM, and trimethoprim ranged 
from 43.5 µM to 0.43 µM. Another plate containing both trimethoprim and 
sulfamethoxazole was distributed 1:23, respectively, and the concentration ranges were 
the same as the individual plate concentrations described above for trimethoprim and 
sulfamethoxazole.  
Imatinib was dispensed across each of these antibiotic’s concentration ranges at 
0.8 µM (IC10), 2.2 µM (IC50), and 5.9 µM(IC90). The wells were normalized to volume 
DMSO and distilled H2O plus 0.3% Tween 20. Control wells included K562 cells 
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incubated with antibiotic only, imatinib at IC10, IC50, and IC90, solvent only (DMSO and 
distilled H2O plus 0.3% Tween 20), and media. The cells were cultured for 48 hours 
using the same protocol as the previous experiments. Seventy-two hours after dispensing 
the cells, the cell proliferation was measured using the CellTiter-Glo® Luminescent Cell 
Viability Assay and a Synergy™ Neo2 Multi-Mode Microplate Reader. 
 A perturbation index was calculated for each antibiotic. The perturbation index 
was determined as the relative luminescence (cell viability) of the antibiotic medication 
plus imatinib at the inhibitory concentration over the relative luminescence (cell viability) 
of imatinib alone. The antibiotic was then judged as antagonistic (>1), synergistic (<1), or 
having no effect on the efficacy of imatinib (=1).  
 
Statistical Analysis 
 The statistical significance of differences observed between experimental and 
controls groups were determined using the one-way analysis of variance (ANOVA) test. 
The post-hoc Dunnett’s test was used to compare each experimental value with an 
imatinib-only control value. A linear trend test was done to determine if the relative 
luminescence (cell viability) increased or decreased systematically as the antibiotic 
concentrations ranged from low to high across the imatinib inhibitory concentrations. 





Determination of Reliable Cell Concentration of K562 Cells for Proliferation 
Assay 
A reliable concentration of K562 cells in 25 µL in a 384-well plate was first 
established to use in a future high-throughput assay. Two thousand K562 cells in 25 µL 
of complete media per well were plated in triplicates and twofold serial dilutions were 
performed. The dilutions ranged from 2,000 K562 cells/25 µL per well to 31 K562 
cells/25 µL per well (8x104 cells/mL to 1,240 cells/mL). Cell proliferation was 
determined at 0 hours, 24 hours, 48 hours, and 72 hours. It has been reported that the 
optimal concentration of K562 cells for inhibition of proliferation assay is 2-5 x 104 
cells/mL.121,122 
 Figure 2 shows the mean number of live cells in 25 µL after a given amount of 
time. Viable cells present in cell suspension were measured using the trypan blue dye 
exclusion test. Each series varies based on the number of cells that were counted at the 
time-point zero hours. The error bars depict the 95% confidence interval of three 
replicates for each cell concentration and time point. When the highest concentration of 
cells (2,000 cells/25 µL or 8 x 104 cells/mL) was plated, cell number expanded ~3.6-fold 
after 72 hours compared to the starting concentration. The cells with the next highest 
starting concentration (625 cells/25 µL or 2.4 x 104 cells/mL) expanded 7.1 times by 72 




375 cells/25 µL (1.5 cells/mL) also significantly proliferated (4.7 times), while the 
remaining concentrations did not demonstrate any significant proliferation (<2 times).  
 After 72 hours, the top two concentrations (2,000 cells/25 µL and 625 cells/25 
µL) are in log phase of cell growth and haven’t reached stationary phase (Figure 2). The 
lower starting concentrations continue to be in a lag phase after 72 hours. Therefore, 
lower plating densities are not optimal for assessment of cellular function and 
proliferation. The results suggest that a density of 2.5-8 x 104 cells/mL of K562 cells is a 
reliable concentration of cells for future experiments.  
 
 
Figure 2. 625 – 2,000 K562 cells/25 µL reliable cell concentration for future 
experiments. Each series varies based on the number of cells that were counted at the 
time-point zero hours (K562 cells/25 µL well): red - 2000, green - 625, purple - 375, 
blue - 188, orange - 125, pink - 62.  The error bars depict 95% confidence interval of 
three replicates for each cell concentration and time point.   
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Association Between Luminescent Signal and Cell Number Using the  
CellTiter-Glo® Luminescent Cell Viability Assay 
 The relationship between luminescence measured with the CellTiter-Glo® 
Luminescent Cell Viability Assay and the number of K562 cells in culture was 
determined by making serial twofold dilutions in a 384-well plate in complete media. The 
dilutions ranged from 84,000 K562 cells/25 µL per well to 328 K562 cells/25 µL per 
well. The luminescence assay was recorded using the CellTiter-Glo® Assay and the 
results are presented in Figure 3.  
 Figure 3 depicts the relationship between luminescence values from the CellTiter-
Glo® Assay and the K562 cell count per well. Luminescence values ranged from 3.9 x 106 
to 4.2 x 104 relative luminescence units (RLU). The error bars depict the 95% confidence 
interval of four replicates (n=2) for each cell concentration with an R2 of 0.956 
(y=46.85x+277928). Concentrations below 21,000 cells/25 µL per well demonstrated an 
R2 of 0.99723 (y=98.515x+24028). The luminescent signal from ~328 cells/25 µL per 
well (the lowest concentration of cells measured) is 168x the background signal from 
medium without cells, indicating that there is not a significant deviance from linearity 
between the luminescent signal and the number of cells from 0 to 8.4 x 105 cells/mL or 
21,000 cells/25 µL. According to Figure 2, a starting concentration of 2,000 K562 
cells/25 µL will proliferate to ~7,000 cells/25 µL after 72 hours of culture, generating a 
luminescence signal at ~8x105, indicating 2,000 K562 cells/25 µL is an acceptable 






Imatinib and Dasatinib IC50 Determination 
 TKI’s are used as the primary treatments for Philadelphia chromosome positive 
leukemia because they inhibit the bcr-abl tyrosine kinase, which leads to a reduction in 
kinase activity. 48 Table 1 outlines the mechanisms of action for imatinib and dasatinib. 
The half maximal inhibitory concentrations (IC50) of imatinib and dasatinib with K562 
cells were determined by dispensing the TKI’s (Imatinib: 30 µM to 3.17 nM; Dasatinib: 
10 µM to 0.5 pM). Cell viability was assessed by measuring luminescence using the cell 
viability assay.  
 The concentration ranges of the first set of experiments with imatinib and 
dasatinib proved to be insufficient to accurately establish upper and lower bounds to 
assess IC50 (Figure 4A and 4B). The original ranges were established at 10 µM to 0.1 nM 
for imatinib and 10 µM to 0.1 nM for dasatinib. The initial results for imatinib depicted  
Figure 3. Linear model of <21,000 cells/25 µL correlated with luminescence output. 
The black line represents the linear model fit to the data points and the red line 
represents the polynomial trendline. The error bars depict the 95% confidence interval. 
of four replicates for each cell concentration with one experimental repeat.  
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only the maximal percent live cells; this indicated that higher concentrations of imatinib 
needed to be examined (Figure 4A). The minimum percent live cells were only seen in 
the initial results of dasatinib, which indicated that lower concentrations of dasatinib 
should be tested (Figure 4B). After adjusting the concentration ranges (imatinib: 30 µM 
to 3.17 nM; dasatinib: 10 µM to 0.5 pM), a better defined sigmoidal curve was produced 
and these data were used to calculate the inhibitory concentrations of both imatinib and 
dasatinib on K562 cells. The three independent experiments with four replicate wells with 
the adjusted concentration ranges are seen in Figure 4C and 4D. 
 The IC50 of imatinib and dasatinib were estimated by using nonlinear regression 
analysis with Prism 7 Software. Imatinib’s IC10 (95% CI, p-value) was estimated to be 
0.8 µM (0.020, <0.001), the IC50 is 2.2 µM (0.009, <0.001), and the IC90 is 5.9 µM 
(0.019, 0.6991). Dasatinib’s IC10 is 0.07 nM (0.032, 0.0093), the IC50 is 0.25 nM (0.015, 
<0.001), and the IC90 is 0.95 nM (0.031, 0.0078). Figure 4C and 4D depicts the 
relationship between the relative luminescence values and imatinib and dasatinib 
concentrations, which were used to calculate the IC50 of each. The error bars for each 
graph depict the 95% confidence interval.  
Table 1 - Mechanisms of Action for Imatinib and Dasatinib 
TKI Mechanism of Action 
Imatinib Targets the well-conserved nucleotide-binding pocket of Abl close to the ATP binding site; binds to the inactive conformation of the 
activation loop of Abl.48 





Figure 5 depicts the residual plots from the three trials with the adjusted 
concentrations for imatinib and dasatinib. The residual plot for imatinib (Figure 5A) 
shows the data are evenly distributed around the regression line. The lower imatinib 
concentrations display increased variance heterogeneity compared to the higher 
concentrations. This can also be noted in Figure 4C: there is more variability in the lower 
imatinib concentrations between the three experiments compared to the higher 
concentrations.  




























Cell proliferation was measured after 72 hours of culture with the CellTiter-
Glo Assay. A) Original range for Imatinib (10 µM to 0.1 nM). B) Original 
range for Dasatinib (10 µM to 0.1 nM). C) Adjusted concentrations for 
Imatinib (30 µM to 3.17 nM), producing sigmoidal curve for the three trials 
performed. D) Adjusted concentrations for Dasatinib (10 µM to 0.5 pM), 
producing sigmoidal curve for the three trials performed. Errors bars for each 
graph depict the 95% confidence interval. 
Figure 4 - K562 Proliferation Curves with Imatinib or 
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K562 Proliferation Curves with Imatinib or Dasatinib 
Added at Various Concentrations 
Figure 4. K562 proliferation curves with imatinib or dasatinib added at various 
concentrations. Cell proliferation was measured after 72 hours of culture with the 
CellTiter-Glo Assay. A) Original Range for Imatinib (10 µM to 0.1 nM). B) Original 
range for Dasatinib (10 µM to 0.1 nM). C) Adjusted concentrations for Imatinib (30 
µM to 3.17 nM), producing a sigmoidal curve for the three trials performed. D) 
Adjusted concentrations for Dasatinib (10 µM to 0.5 pM), producing sigmoidal curve 





The dasatinib residual plot also shows a consistent distribution around the 
regression line (Figure 5B). However, during experiment 1 and 2, a consistent deviation 
was seen between the dasatinib concentrations 0.52 nM and 0.32 nM (log -0.3 and log -
0.49) shown in Figure 4D and 5B, indicated by an elevation in relative luminescence 
units beyond flanking dasatinib concentrations. Experimentally, a change in top stock 
concentrations occurred between these two dasatinib concentrations from 1 mM to 1 µM 
because the instrument cannot accurately dispense a volume below 20 pL. After 
experiments 1 and 2, the stock concentrations of dasatinib were changed from 1 mM and 
1 µM to 20 µM and 100 nM. This change in stock concentration altered the smallest 
amount of volume that was dispensed into the wells while keeping the final concentration 
the same. This change in protocol in experiment 3 caused those two concentrations (0.52 
nM and 0.32 nM) to become significantly closer to the regression line.   
 
 












































The errors bars depict the 95% confidence interval. 
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Figure 5 - Residual Plots for Imatinib and Dasatinib IC50 
Determination
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Figure 5. Residual plots for imatinib and dasatinib IC50 determination. The errors bars 
depict the 95% confidence interval.  
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Solvents Used in TKI Efficacy Assay 
Imatinib mesylate and dasatinib were dissolved in DMSO. However, DMSO has 
shown to be toxic to human cell lines at concentrations as low as 2-4% and it was 
important to determine the concentration of DMSO that was nontoxic to K562 cells.123 
Figure 6 depicts theK562 cell proliferation curve that was created when different amounts 
of DMSO were administered to K562 cells at the starting concentration 2,000 K562 
cells/25 µL. Based on these data, the amount of DMSO is imperative to getting consistent 
results with K562 cells and must be kept below 0.5% to not get DMSO-biased results. In 
order to keep DMSO concentrations low, a higher stock concentration of Imatinib (5 
mM) was created to prevent further issues with DMSO. DMSO volume was kept constant 
for all wells.  
 All of the antibiotics were dissolved in distilled H2O with 0.3% Tween 20. Tween 
20 is also known to be toxic to cells at certain concentrations.124 The results showed that 
concentrations of <5% of the water/tween 20 solution did not have detective influence on 
the viability of K562 cells; however, >10% of the water/tween 20 solution did show a 
significant impact on the K562 cells viability. Figure 7 depicts the relationship between 
increasing water/tween 20 solution concentration and K562 cells viability (measured in 
relative luminescence units). These data indicated that keeping the concentration of 
Tween 20 low was important to maintain unbiased results. Higher top stock 


























Increasing volume of DMSO shows a decrease in relative 
luminescence units, indicating a decrease in percentage of live K562 
cells. The error bars depict the 95% confidence interval. 
Figure 6 - DMSO Toxicity to K562 CellsDMSO Toxicity to K562 Cells 
Figure 6. DMSO toxicity to K562 cells. Increasing volume of DMSO shows a 
decrease in r lative luminescence units, indicating a decrease in percentage of live 
















































   
   
   
   
   
               
Increasing concentration of the 0.3% Tween 20 H20 solution 
(Water/Tween 20) shows toxicity to K562 cells. The error bars 
depict the 95% confidence interval. 
Figure 7 - Tween Toxicity to K562 Cells
Tween Toxicity to K562 Cells 
Figure 7. Tween toxicity to K562 cells. Increasing concentration of the 0.3% Tween 
20 H20 solution (Water/Tween 20) shows toxicity to K562 cells. The error bars depict 
the 95% confidence interval.  
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Determination of Imatinib Efficacy after Co-incubation with Antibiotics 
 Imatinib efficacy after the addition of antibiotics was determined by culturing the 
TKI at the IC10, IC50, and IC90 determined in the previous experiments and an antibiotic 
at ten-times above and below clinically relevant concentrations with K562 cells. Cell 
viability was determined 48 hours after dispensing the drugs. 
 Figure 8A-J depicts the results of the experiments that examine imatinib’s ability 
to suppress K562 proliferation after co-incubation with antibiotics. Figures 8A, C, E, G, 
and I compare the concentration of the antibiotics with the cell viability (measured in 
relative luminescence units) when Imatinib is added at IC10, IC50, and IC90. Figures 8B,  
D, F, H, and J compare the perturbation ratio of luminescence with imatinib at IC10, IC50, 
and IC90 co-incubated with the antibiotics over the luminescence of imatinib alone (at 
IC10, IC50, and IC90, respectively). A perturbation ratio equal to one indicates that the 
antibiotic did not alter the efficacy of imatinib relative to imatinib treatment alone. A 
ratio greater than one suggests the antibiotic is antagonistic and reduces the ability of 
imatinib to decrease K562 cell proliferation. A ratio less than one designates the 
antibiotic to be synergistic, which causes an even greater reduction in K562 cell 
proliferation.  
Gentamicin and ceftazidime appear to have a perturbation ratio slightly lower 
than one for all imatinib concentrations (Figure 8B and D), which indicates they have a 
slight antagonistic effect on imatinib, whereas sulfamethoxazole and trimethoprim are 
fairly equal to one and have no effect (Figure 8F, H and J). Statistically, gentamicin and 
ceftazidime show to be significant through the ANOVA post-hoc linear trend test, which 
indicates that the slopes in Figure 8A and C have a significant slope not equal to zero 
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K562 Cell Proliferation with Co-Incubation of Imatinib and 
Antibiotics and Perturbation Ratio 


































































































Cell proliferation was measured in luminescence units after 72 hours of culture. Imatinib concentrations were the 
previous determined IC10, IC50, and IC90. Imatinib was co-incubated with A) gentamicin, C) ceftazidime, E) 
sulfamethoxazole, G) trimethoprim, and I) trimethoprim and sulfamethoxazole distributed 1:23, respectively. 
Controls contain no imatinib, only antibiotics. The perturbation ratio of luminescence with imatinib (IC10, IC50, IC90) 
and antibiotic over the luminescence with only imatinib (IC10, IC50, IC90) compared to the concentrations of 
antibiotics is seen in the following figures with antibiotics: B) gentamicin, D) ceftazidime, F) sulfamethoxazole, H) 
trimethoprim, and J) trimethoprim and sulfamethoxazole distributed 1:23, respectively. The errors bars depict the 
95% confidence interval.
Figure 8 - K562 Cell Proliferation with Co-Incubation of Imatinib and 
Antibiotics and Perturbation Ratio
Figure 8. K562 cell proliferation with co-incubation of imatinib and antibiotics and 
perturbation ratio. Cell proliferation was measured in luminescence units after 72 
hours of culture. Imatinib concentrations were the previously determined IC10, IC50, 
and IC90. Imatinib was co-incubated with A) gentamicin, C) ceftazidime, E) 
sulfamethoxazole, G) trimethoprim, and I) trimethoprim and sulfamethoxazole 
distributed 1:23, respectively. Controls contain no imatinib, only antibiotics. The 
perturbation ratio of luminescence with imatinib (IC10, IC50, and IC90) and antibiotics 
over the luminescence with only imatinib (IC10, IC50, and IC90) compared to the 
concentrations of antibiotics is seen in the following figures with antibiotics: B) 
gentamicin, D) ceftazidime, F) sulfamethoxazole, H) trimethoprim, and J) 
trimethoprim and sulfamethoxazole distributed 1:23, respectively. The error bars 







K562 Cell Proliferation with Co-Incubation of Imatinib and 
Antibiotics and Perturbation Ratio 
Figure 8 continued.  
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Figure 8 cont. - K562 Cell Proliferation with Co-Incubation of Imatinib and 
ntibiotics and Perturbation Ratio
Cell proliferation was measured in luminescence units after 72 hours of culture. Imatinib concentrations were the 
previous determined IC10, IC50, and IC90. Imatinib was co-incubated with A) gentamicin, C) ceftazidime, E) 
sulfamethoxazole, G) trimethoprim, and I) trimethoprim and sulfamethoxazole distributed 1:23, respectively. 
Controls contain no imatinib, only antibiotics. The perturbation ratio of luminescence with imatinib (IC10, IC50, 
IC90) and antibiotic over the luminescence with only imatinib (IC10, IC50, IC90) compared to the concentrations of 
antibiotics is seen in the following figures with antibiotics: B) gentamicin, D) ceftazidime, F) sulfamethoxazole, H) 
trimethoprim, and J) trimethoprim and sulfamethoxazole distributed 1:23, respectively. The errors bars depict the 
95% confidence interval.
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 (Table 2; P=0.003 and <0.0001, respectively). However, they were not statistically 
significant through the ANOVA or Dunnett test (Table 2). This indicates that gentamicin 
and ceftazidime have a significant effect on the proliferation of K562 cells, but the 
concentration of imatinib does not alter the effect. Sulfamethoxazole, trimethoprim or the 
sulfamethoxazole:trimethoprim ratio were not seen significant in any of the three tests 
(Table 2).  
The controls for these tests are shown in Figure 9. The controls relative 
luminescence values vary between experiments, but they all vary in the same direction. 
This indicates that the results are precise, but not as accurate. However, the accuracy is 
not as important as the precision for obtaining these results because a ratio is used to 





Table 2 – ANOVA and Post-Hoc Test Results on Co-Incubation of Imatinib and 
Antibiotics 
 ANOVA Dunnett Test 
Linear Trend 
Test 
 P value 
Any Comparisons 
Significant (P<0.05)? P value 
Gentamicin 0.1615 No 0.003* 
Ceftazidime 0.2667 No <0.0001* 
Sulfamethoxazole 0.2577 No 0.1248 





























































Figure 9 - Control Groups for Co-Incubation of 



















Cell proliferation in each control group was measured in luminescence units after 
72 hours of culture. The error bars depict the 95% confidence intervals.  
Control Groups for Co-Incubation of Imatinib and 
Antibiotics Experiments 
Figure 9. Control groups for co-incubation of imatinib and antibiotics experiments. 
Cell proliferation in each control group was measured in luminescence units after 72 
hours of culture. The error bars depict the 95% confidence intervals.  
DISCUSSION 
 
The development of an assay that investigates the effect of tyrosine kinase 
inhibitors on the K562 cell line when incubated with other drugs is an important aspect of 
this thesis work because it can be used in future pharmaceutical research for tyrosine 
kinase inhibitors’ ability to suppress K562 proliferation when administered with other 
drugs. Previous assays have been established to investigate K562 cell viability with 
TKI’s and other drugs including other commercial luciferase luminescence cell viability 
assays, high performance liquid chromatography (HPLC), MTT cell proliferation assays, 
resazurin fluorescent cellular health indicators, and flow cytometry.125–129 However, the 
protocol for this assay used innovative technology that has been proven to be robust and 
accurate. 
Lee et al. used 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) to measure K562 proliferation after incubation.129 This protocol requires MTT to 
be incubated in the wells for 3-4 hours, removed through aspiration, and the absorbance 
of the formazan crystals (dissolved in DMSO) are measured.129 This assay is highly 
sensitive; however, it requires many wash steps and cellular metabolic rate can interfere 
with the accuracy of the measurements, which can make this assay biased.130 Similar to 
the protocol developed for this thesis work, the MTT assay is suitable for high-
throughput screening with the assistance of technology.  
The technology I used while developing this assay also allows for this protocol to 
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be used in high-throughput screening. The Freedom EVO® liquid handling workstation 
improved pipetting speed and reduced contamination, which improve the efficiency of 
these cell viability experiements.131,132 The HP D300 Digital Dispenser has been tested 
against other cytotoxicity assays and determined to produce similar results as more 
traditional methods such as the pin tool.133 This dispenser saves time by eliminating serial 
dilutions and requires low compound consumption.133 This project utilized many of the 
features of the HP D300 Dispenser including randomized design and solvent 
normalization. 
Other researchers, including Yamakawa et al., have used resazurin reduction 
assays like AlamarBlue®, which utilizes the reducing environment in viable cells to 
convert resazurin into resorufin, a compound that is highly fluorescent, to measure K562 
cell proliferation.127 Similar to the CellTiter-Glo® Luminescent Cell Viability Assay, few 
wash steps are involved. However, resazurin reduction assays are not cytotoxic like the 
CellTiter-Glo® Luminescent Cell Viability Assay, so follow-up assays can be performed 
on the same cells as the resazurin reduction assay. This feature is not necessary for this 
protocol that examines drug-drug interactions in the K562 cell line, but it may be a viable 
alternative to the CellTiter-Glo® Luminescent Cell Viability Assay if follow-up assays 
want to be performed in the future. 
During the development of this assay, all TKI’s were dissolved in DMSO, which 
proved to be a limitation to the assay. DMSO has been reported to have low toxicity to 
cells at concentrations <10%.123 However, concentrations higher than 0.5% appeared to 
have a negative impact on the K562 cell proliferation during the development phase of 
this assay. Galvao et al. also reported similar results, that a low dose of DMSO (>1%) can 
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cause cellular toxicity through plasma membrane pore formation. Due to the DMSO 
toxicity, it was necessary for higher stock concentrations of TKI’s to be used to reduce 
the amount of DMSO administered to cells.  
The reliable K562 cell concentration was determined to be ~625-2,000 cells/25 
µL, which was the same concentration that other researchers have derived to be a valid 
initial cell concentration.134 After the assay was developed, it was validated by measuring 
cell proliferation with the addition of TKI’s. The maximal inhibitory concentration of 
imatinib and dasatinib was determined by using the established protocol and the available 
instrumentation. This was an important step in developing an appropriate TKI-drug 
testing procedure because IC50 concentrations can vary based on the lab conditions, 
reagents, cell line mutations, and laboratory instrumentation. Published research studies 
have used a variety of IC50’s for imatinib (0.15 - 4.4 µM) and dasatinib (0.35 - 1 nM) 
using the K562 cell line based on the conditions established through their protocol.59,135–
140 The combination of the IC10, IC50, and IC90 that were obtained from the assay 
development fits well within published values of imatinib.  
However, the log IC10 and IC50 values that were produced for imatinib and 
dasatinib varied significantly. This may have been caused by the initial concentration of 
K562 cells that were cultured in the 384-well plate being slightly different. If the 
antibiotics were added across all of the concentrations of imatinib, there may have been a 
change in the effectiveness of imatinib. However, the three concentrations that were 
tested (IC10, IC50, and IC90) were significantly different and they proved there was no 
change in imatinib efficacy across all three points.  
 After discovering appropriate TKI concentrations to test, imatinib was tested with 
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antibiotics commonly given to leukemia patients. Gentamicin, ceftazidime, trimethoprim, 
or sulfamethoxazole showed to not have a significant impact on the ability of imatinib to 
reduce K562 cell proliferation. Due to the time limit, this research was conducted with a 
low number of replicates for the imatinib-antibiotic drug combination. Ideally, 3-5 
replicates would have produced a larger, less-biased data set to generalize the results for 
the population. However, this assay has the potential to conduct many more tests of 
imatinib-antibiotic interactions and other drug-drug interactions. 
 One limitation that should be noted is the control groups that were investigated 
were not similar throughout the different time-points. For example, the DMSO-only 
control varied from 1.3x106 to 1.6x106 relative luminescence units across all three 
experiments. This also may have been caused by the initial concentration of K562 cells 
plated being dissimilar. Although the values are all different, the ratios between them are 
similar. The first experiment has relatively less proliferation across all of the controls 
compared to the next two and the third experiment has the highest proliferation.  
There was no antagonistic control among the control groups, which also proved to 
be a limitation to the experimental design. Without an antagonistic control, there is no 
independent variable that indicates an antagonistic effect to evaluate the protocol, 
reagents, and the equipment for experimental error. During future use of this protocol, 
drugs that indicate an antagonistic effect with imatinib should be further evaluated for use 
as a future antagonistic control in the experimental design. Similarly, drugs that are 
revealed to by synergistic should be evaluated for use as a synergistic control.  
Drug-drug interactions have previously been studied in K562 cell lines, and both 
synergistic and antagonistic effects have been found. Tanespimycin, a derivate of the 
	 49	
antibiotic geldanamycin, was found to have synergistic activities with imatinib in AML 
patient cells by inhibiting Pgp-mediated imatinib efflux, thus increasing intracellular 
imatinib levels.141 Another synergistic effect reported is that ABT-737, an analogue of an 
experimental orally active anticancer drug called navitoclax, enhances the effect of 
INNO-406, a second-generation BCR-ABL inhibitor named bafetinib.125 Antagonistic 
activity against imatinib was found with the antipsychotic drug lithium chloride, where a 
combination of the two was less effective in decreasing cellular proliferation than 
imatinib alone.142 The effectiveness of imatinib has also been known to be altered by St. 
John’s wort, rifampicin, antacids that elevate gastric pH, and inhibitors of hOCT1.99,103–
105 
 Although certain drugs have shown to have synergistic or antagonistic effects on 
TKI’s, many drugs have been examined and determined to have no effect on TKI 
efficacy, similar to my findings with gentamicin, ceftazidime, and bactrim.125 While in 
vitro studies cannot predict the in vivo microenvironment, like cytokine activity for 
example, that may contribute to the interactions that would occur with drugs, it is a good 
predictor of significant changes that can be caused by drug interactions. It is important 
for clinicians who are prescribing treatments regimens to leukemia patients to understand 
how concomitantly administered drugs can alter their effect. These physicians can now 
feel more confident when prescribing gentamicin, ceftazidime, or bactrim with imatinib 
to a patient because the antibiotics appear to have no effect on the efficacy of imatinib.   
 While no statistically significant effect was found between the antibiotics and 
imatinib under the testing conditions, a slight synergistic effect has been observed 
between gentamicin and imatinib. Potentially, under different conditions, this effect may 
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become significant and further testing may be necessary to further explore the 
relationship between gentamicin and imatinib.  
 One of the aims of this thesis work was to help develop an approach to testing 
leukemic cells’ proliferation after the addition of one or more drugs. A high-throughput, 
semi-automated in vitro assay has been produced that can be used in the future to 
determine how other drugs that are commonly given to chronic myeloid leukemia 
patients affect TKI’s. Some examples of drugs to be tested include acetaminophen, 
diphenhydramine, ondansetron, oxycodone, lorazepam, voriconazole, and morphine. This 
protocol can also be used to determine the IC50’s of other TKI’s (nilotinib and ponatinib) 
and how various pharmaceuticals impact their function. 
 In addition, other Ph+ leukemic cell lines with different features from the K562 
cell line can be tested to determine if variations in cell type, age/sex of patient, or disease 
status impact the effect medications have on TKI’s to reduce cellular proliferation. The 
K562 cell line is erythrocytic, derived from a pleural effusion of a 53 year old female in 
CML blast crisis, and does not carry the classical Ph chromosome (but does have 
rearrangement of BCR and translocation of ABL).143,144 One example of an alternative is 
the SUP-B15 cell line. The SUP-B15 is a B-cell precursor from a 9-year-old male with 
ALL during his second relapse.143,145 Ph+ ALL is much more common in children 
compared to adults, and therefore, studying a cell line that represents the younger ALL 
population would be informative for clinicians while administering supportive 
medications.  
 In this experiment, the TKI was dispensed at the same time as the antibiotics. 
However, in the clinic, antibiotics may be given a few days prior to the imatinib dose, 
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which may effect how the antibiotics interact with the cells and the TKI. To fully 
understand the clinical impacts of co-administration of TKI’s and antibiotics, it would be 
necessary to pre-incubate the antibiotics in vitro before adding the TKI.  
This approach to drug-drug interaction testing has the potential to be used in the 
identification of personalized treatments for patients with Ph+ leukemia. Some of these 





In summary, using innovative technology and assay procedures, an effective, 
high-throughput in vitro assay has been developed that can be used to determine drug-
drug interactions that would impact patients with Ph+ leukemia using the K562 cell line. 
This assay was validated by testing K562 cell proliferation with various concentrations of 
the TKI’s imatinib and dasatinib. Maximal inhibitory concentrations were determined 
and used to concomitantly test imatinib and commonly used antibiotics including 
gentamicin, ceftazidime, and bactrim (sulfamethoxazole and trimethoprim). While no 
statistically significant interactions were detected for any of the antibiotics, a slight 
synergistic effect has been observed for gentamicin and may be studied in the future. 
Finally, this new methodology can be used as a tool to predict drug efficacy and 
determine responses in Ph+ leukemia patients that will lead to personalized treatment.  
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